ERBB2 and breast carcinoma: In HER2-overexpressing breast cancer cells, it is considered that Wnt3 overexpression may activate Wnt/β-catenin transactivating EGFR, which can lead to a partial-EMT that could be important in understanding trastuzumab resistance in these cells[60].